MA54943A - Production de compositions comprenant deux anticorps ou plus - Google Patents

Production de compositions comprenant deux anticorps ou plus

Info

Publication number
MA54943A
MA54943A MA054943A MA54943A MA54943A MA 54943 A MA54943 A MA 54943A MA 054943 A MA054943 A MA 054943A MA 54943 A MA54943 A MA 54943A MA 54943 A MA54943 A MA 54943A
Authority
MA
Morocco
Prior art keywords
antibodies
compositions
production
Prior art date
Application number
MA054943A
Other languages
English (en)
Inventor
Alexander Berthold Hendrik Bakker
Robert Paul Doornbos
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MA54943A publication Critical patent/MA54943A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA054943A 2019-02-14 2020-02-13 Production de compositions comprenant deux anticorps ou plus MA54943A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19157286 2019-02-14
EP19178542 2019-06-05

Publications (1)

Publication Number Publication Date
MA54943A true MA54943A (fr) 2021-12-22

Family

ID=69771002

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054943A MA54943A (fr) 2019-02-14 2020-02-13 Production de compositions comprenant deux anticorps ou plus

Country Status (14)

Country Link
US (1) US20220127375A1 (fr)
EP (1) EP3924377A1 (fr)
JP (2) JP7375027B2 (fr)
KR (1) KR20210126699A (fr)
AU (2) AU2020221649B2 (fr)
BR (1) BR112021016092A2 (fr)
CA (1) CA3130246A1 (fr)
IL (1) IL285489A (fr)
MA (1) MA54943A (fr)
MX (1) MX2021009769A (fr)
PH (1) PH12021552001A1 (fr)
SG (1) SG11202108840XA (fr)
TW (2) TW202521568A (fr)
WO (1) WO2020167122A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200291130A1 (en) * 2017-03-31 2020-09-17 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
CN118027197A (zh) * 2017-07-06 2024-05-14 美勒斯公司 调节由细胞表达的生物活性的抗体
EP4263597A2 (fr) * 2020-12-18 2023-10-25 Kiniksa Pharmaceuticals, Ltd. Compositions de protéines et leurs procédés de production et d'utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092719A1 (en) * 2002-09-17 2004-05-13 Eszter Birck-Wilson Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds
WO2004106375A1 (fr) * 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Banque de fab pour la preparation de fab anti-vegf et antirabique
EP2009101B1 (fr) * 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Procede de modification d'anticorps pour purifier un anticorps bispecifique
WO2008027236A2 (fr) 2006-08-30 2008-03-06 Genentech, Inc. Anticorps multispécifiques
EP2147594B1 (fr) 2008-06-27 2013-11-13 Merus B.V. Mammifères non humains produisant un anticorps
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
CA2785414C (fr) * 2009-12-25 2019-01-22 Tomoyuki Igawa Procede de modification de polypeptide pour purifier un multimere de polypeptide
US9248181B2 (en) * 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
CN105473612A (zh) * 2013-08-19 2016-04-06 豪夫迈·罗氏有限公司 用羟基磷灰石层析分离双特异性抗体和双特异性抗体生产副产物
MX2019014572A (es) * 2017-06-05 2020-07-29 Janssen Biotech Inc Métodos de ingeniería de carga superficial para la producción de anticuerpos biespecíficos.

Also Published As

Publication number Publication date
CA3130246A1 (fr) 2020-08-20
AU2025204857A1 (en) 2025-07-17
TW202521568A (zh) 2025-06-01
EP3924377A1 (fr) 2021-12-22
US20220127375A1 (en) 2022-04-28
PH12021552001A1 (en) 2022-09-19
TWI872049B (zh) 2025-02-11
KR20210126699A (ko) 2021-10-20
JP2023171492A (ja) 2023-12-01
IL285489A (en) 2021-09-30
WO2020167122A1 (fr) 2020-08-20
JP2022520972A (ja) 2022-04-04
AU2020221649A1 (en) 2021-09-02
JP7656002B2 (ja) 2025-04-02
JP7375027B2 (ja) 2023-11-07
TW202045132A (zh) 2020-12-16
AU2020221649B2 (en) 2025-03-27
SG11202108840XA (en) 2021-09-29
MX2021009769A (es) 2021-09-08
BR112021016092A2 (pt) 2021-10-26

Similar Documents

Publication Publication Date Title
MA49043A (fr) Formulation stable d'anticorps
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
MA51734A (fr) Anticorps se liant à gprc5d
MA49726A (fr) Formulation d'anticorps anti-cgrp
EP3883970A4 (fr) Anticorps anti-b7-h3
MA46525A (fr) Anticorps anti-lag-3 et compositions
EP3898698A4 (fr) Anticorps spécifiques à muc18
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA55600A (fr) Anticorps anti-ige
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
MA47816A (fr) Composition pharmaceutique comprenant du sélexipag
EP3496753A4 (fr) Formulation d'anticorps anti-pd-1
EP3807318A4 (fr) Constructions d'anticorps multi-spécifiques
EP3621640A4 (fr) Constructions d'anticorps d'acide nucléique optimisées
EP4271712A4 (fr) Anticorps anti-hvem
MA51903A (fr) Formulations d'anticorps b7-h4
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
EP3995582A4 (fr) Anticorps anti-epha4
MA54139A (fr) Formulation d'anticorps
EP3927729A4 (fr) Formulation d'anticorps thérapeutique
MA49289A (fr) Anticorps se liant à steap-1
EP3831851A4 (fr) Anticorps anti-btla
MA53466A (fr) Formulation stable d'anticorps anti-osmr